Rocket Doctor AI Inc. (CSE: AIDR) announced strong operational results for the third quarter ended September 30, 2026, completing 53,348 total patient visits across Canada and the United States. The Vancouver-based digital health company simultaneously disclosed it expects to report record quarterly revenue for Q3 2026, a milestone investors may view as confirmation that its multi-payer growth strategy is gaining traction. The announcement highlights a 56% quarter-over-quarter surge in U.S. completed visits and a 24% year-over-year increase in Canadian visits.

Key Points

  • Rocket Doctor AI Inc. (CSE: AIDR, OTC: AIRDF, Frankfurt: 939)
  • The company completed 53,348 patient visits in Q3 2026 — 6,101 in the U.S. and 47,247 in Canada — and expects to report record quarterly revenue for the period.
  • U.S. visits rose 56% quarter-over-quarter from 3,911 in Q2 2026; U.S. clinical hours reached 2,634, up 33% from 1,987.5 in Q2 2026; Canadian visits grew 24% year-over-year from 37,960 in Q3 2025.
  • Investors may be watching for the official Q3 2026 financial results to confirm whether anticipated record revenue aligns with reported figures once cash collections are recognised.

Rocket Doctor AI's Q3 2026 Patient Visit Volumes Across Canada and the U.S.

The company completed 6,101 U.S. patient visits and 47,247 Canadian patient visits during the quarter, totalling 53,348 — surpassing 50,000 combined visits in a single quarter for the first time according to the release. U.S. clinical hours also expanded materially, reaching 2,634 hours in Q3 2026 compared with 1,987.5 hours in Q2 2026, an increase of 33%. The company states these clinical hours and completed visits are important leading indicators of its operational and financial performance as the platform scales across North American markets.

Multi-Payer Strategy Driving U.S. Volume Growth

The release attributes the 56% quarter-over-quarter rise in U.S. visits to the continued execution of the company's multi-payer strategy. Rocket Doctor AI states it has built a network of over 20 in-network payer agreements spanning commercial, Medicare Advantage, and Medicaid verticals. The company also permits out-of-network patients access to its platform during this early stage of U.S. market development to drive adoption, while noting that reimbursement for out-of-network visits is generally not expected and that any amounts recovered from such claims will only be recognised upon actual cash receipt.

Revenue Recognition Lag and the Path to Record Q3 Results

The company cautions that because certain U.S. revenues are recognised on a cash basis, a timing lag exists between completed patient visits and corresponding revenue recognition. This lag affected Q2 reported results, where significant volume growth was not immediately reflected financially. With U.S. visits rising a further 56% in Q3, the company states it expects cash collections to begin catching up with clinical activity, supporting its guidance for record quarterly revenue for the period ended September 30, 2026. Actual reported figures will be disclosed in the company's forthcoming financial results.